Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At the 16th Annual General Meeting of Shareholders held on March 26, 2024, all proposed agendas—including approval of financial statements, appointment of directors and auditor, approval of remuneration limits, and granting of stock options—were approved as originally submitted. 📊 [Key Disclosure Details & Financial Highlights] 📝…

Read More “[Disclosure] ALTEOGEN (196170) – Results of Annual General Meeting of Shareholders / 2024-03-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that all agenda items presented at its 33rd Annual General Meeting of Shareholders, including the approval of financial statements, a cash dividend of KRW 500 per common share, and the re-appointment of Inside Director Jin-Seok Seo, were approved as original proposals. 📊 [Key Disclosure…

Read More “[Disclosure] Celltrion (068270) – Results of Annual General Meeting of Shareholders / 2024-03-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion disclosed a correction to its FY2023 year-end cash dividend, updating the total dividend amount to approximately KRW 103.6B (KRW 500 per share) following changes in eligible shares and the confirmation of the AGM date. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Celltrion (068270) – Decision on Cash/In-Kind Dividend (Correction) / 2024-03-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for CT-P39 (Omalizumab), a biosimilar to Xolair, covering 30 European countries. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment…

Read More “[Disclosure] Celltrion (068270) – CHMP Positive Opinion Granted for CT-P39 (Xolair Biosimilar) by EMA / 2024-03-25” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has adjusted the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 147.3B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to May 31, 2024, following consultations with the client. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen received an ‘Unqualified’ audit opinion from Ichon Accounting Corporation for both consolidated and separate financial statements, with consolidated revenue increasing significantly to KRW 96.5B compared to the previous fiscal year. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why…

Read More “[Disclosure] ALTEOGEN (196170) – Submission of Audit Report / 2024-03-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At its 13th Annual General Meeting of Shareholders, Samsung Biologics approved all submitted agenda items as originally proposed, including the financial statements with revenue of KRW 3.69T, the appointment of Seung-Hwan Suh as Outside Director and Audit Committee Member, and the approval of the limit on…

Read More “[Disclosure] Samsung Biologics (207940) – Results of Annual General Meeting of Shareholders / 2024-03-15” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has signed a pharmaceutical contract manufacturing agreement worth approximately KRW 92.8B (USD 70.6M) with Merck Sharp & Dohme (Switzerland) GmbH. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue Recognition and Contract Condition Adjustments over the Term…

Read More “[Disclosure] Samsung Biologics (207940) – Sales / Supply Contract / 2024-03-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Driven by increased technical service revenue and milestone payments from ALT-B4, consolidated revenue surged 235% YoY to KRW 96.5B, significantly narrowing both operating and net losses. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying Preliminary Financial Results and…

Read More “[Disclosure] ALTEOGEN (196170) – Change in Revenue or Income Structure Exceeding 30% (15% for Large Corporations) / 2024-03-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen decided to hold its 16th Annual General Meeting of Shareholders on March 26, 2024, at the Daejeon Convention Center to vote on agenda items including financial statement approval, director/auditor appointments, and stock option grants. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Resolution on Calling of General Meeting of Shareholders / 2024-03-11” »